OCUL Projected Dividend Yield
Ocular Therapeutix Inc ( NASDAQ : OCUL )Ocular Therapeutix, Inc. is a biopharmaceutical company engaged in the development and commercialization therapies for eye conditions, including wet age-related macular degeneration (wet AMD), diabetic retinopathy and other ocular diseases. Co.'s commercial product, DEXTENZA, treats ocular inflammation and pain following eye surgery and ocular itching due to allergic conjunctivitis. Co. is also developing OTX-DED for short-term dry eye disease treatment and OTX-CSI for chronic dry eye disease management. It is conducting a Phase III trial for AXPAXLI to treat wet AMD and are also advancing PAXTRAVA in Phase III clinical development for primary open-angle glaucoma or ocular hypertension. 21 YEAR PERFORMANCE RESULTS |
OCUL Dividend History Detail OCUL Dividend News OCUL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |